We need to have that discussion with our senior executive team, and then with the board of AstraZeneca. We are exploring different options, but it is far too early at this stage to conclude that (process), hopefully before the year ends, we will have a better view how to move forward in the next few years.

Ruud Dobber

This is promising news for the 30 million people living with type-2 diabetes in the United States, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke.

It’s not sustainable to do it without profits, but it’s too early now to speculate about that.